Direct to consumer testing can potentially be quite dangerous without appropriate regulations and support to fully understand the implications of the information a consumer receives.

QIAGEN to Aquire STAT-Dx

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing in second half 2018 in Europe and later in the U.S.

Stuff to Read, Week 6

Would you pay to give your child a genetic advantage, to make them smarter than their peers, taller, or more beautiful? This is a question that will become relevant within a few decades, according to Big Think — if not sooner.